Nu-Med Plus (NUMD) Capital Expenditures (2012 - 2018)

Nu-Med Plus (NUMD) posted Capital Expenditures of $1.0 for Q4 2018, up 100.09% sequentially from -$1101.0 in Q4 2014.

Nu-Med Plus (NUMD) Capital Expenditures (2012 - 2018) Analysis & Trends

Nu-Med Plus has reported Capital Expenditures for 4 years, with the latest figure at $1.0 in Q4 2018.

Quarterly Capital Expenditures changed N/A year-over-year to $1.0 in Q4 2018, while the trailing twelve-month figure through Dec 2019 was $1.0 (changed 0.0% YoY) and the FY2018 annual result came in at -$5025.0, changed N/A from the prior year.
Capital Expenditures rose to $1.0 in Q4 2018 per NUMD's latest filing, from -$1101.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $1.0 in Q4 2018 and troughed at -$1101.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Abbott Laboratories	199.12 Bn	193.52 Bn	7.27 Bn	497.00 Mn
2	Stryker	126.18 Bn	122.71 Bn	4.50 Bn	202.00 Mn
3	Medtronic	118.63 Bn	109.41 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	72.75 Bn	72.21 Bn	3.85 Bn	195.00 Mn
5	Edwards Lifesciences	52.10 Bn	47.85 Bn	1.35 Bn	66.90 Mn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	84.70 Mn
7	GE HealthCare Technologies	33.68 Bn	31.57 Bn	2.18 Bn	100.00 Mn
8	Koninklijke Philips	26.32 Bn	23.00 Bn	4.55 Bn	-74.39 Mn
9	Steris	23.10 Bn	22.62 Bn	684.20 Mn	87.50 Mn
10	Nu-Med Plus	2.03 Mn	2.02 Mn	-	-

Download Data